Therapeutics; Helicobacter pylori; Duodenal Ulcer; Stomach Ulcer; Pharmaceutical Preparations; 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin Study on the effect of PAC500 regimen in the treatment of peptic ulcer disease with H. pylori (+) in 33 patients. The results showed that, this regimen is good with the mean value of pain relief is 6.5 days in addition to the high percentage of ulcer healing (96.9%: protocol and 93.9%: intention of treatment) and the high percentage of H.pylori eradication (87.5%: protocol and 84.8%: intention of treatment). Beside, there is an improvement of the acute gastritis lesion on gastric mucosa after the eradication. But the high percentage of side-effects (81.8%) must be considered, bitter sensation of the mouth is the most common and can be tolerated. Reported only 1 case had to withdraw this trial because of vomitting side-effect
Therapeutics ; Helicobacter pylori ; Duodenal Ulcer ; Stomach Ulcer ; Pharmaceutical Preparations ; 2-Pyridinylmethylsulfinylbenzimidazoles ; Amoxicillin ; Clarithromycin

56 patients with gastric ulcers were treated by triple therapy with Nexium, Ospamox and Klacid (NOK).45 days after treatment, 89.3% patients had no gastric pain; 92.8% patients had ulcer healing, HP eradication rate 94.6% at 6 months and 12 months after treatment, 95% and 93.8% patients had ulcer healing; HP eradication rate was 90% and 90.6%; gastric pain and ulcer recurrence was 7.5% and 6.3%, respectively; HP-positive return rate was 10% and 9.4%
Stomach Ulcer, Helicobacter pylori, Therapeutics